‘Fat jabs left me so depressed it was like having The Deer Hunter theme on repeat in my head'
Within a week of my first injection I felt a deep despair, seemingly from nowhere. Nothing had happened in my work or social life to trigger it. For a few days I searched for a cause, confused and concerned about where this blackness had come from. Suddenly, to an almost absurd, comical extent, existence seemed bleak and irredeemable. It was like having the theme tune to 1978's war drama The Deer Hunter playing in my head on repeat.
After the initial shock, I had to somehow find a way to recognise this state for what it was: artificially induced – the mental equivalent of fake news.
I have known lots of people with 'real' depression: the kind that keeps a person in bed for a week as if there were a weight tied to their body. The kind that waxes and wanes without reason, making it hard for those around them to empathise. I'd never known that feeling, yet here it was squatting on top of me day after day.
Using weight-loss injections produced no other side effects. I have been sleeping well, I've not felt any nausea and I have undoubtedly lost weight, which was the whole point of this expensive experiment in the first place.
Much of what has been written about the mental health impact of these treatments has been on either the positive effects of losing weight – improved self esteem – and how some who experience ADHD report a heightened sense of focus and concentration.
Nowhere in the literature of the companies that make the treatments, or those who sell it, is there any suggestion that depression is a verifiable risk. Side effects are listed as nausea and vomiting, constipation, diarrhaea, reflux, headaches and fatigue. So much the same as a long stag weekend, rather than a continuous vigil at the edge of the abyss.
The medications in question are known as 'glucagon-like peptide-1 receptor agonists' (examples are semaglutide in Ozempic and Wegovy, and tirzepatide in Mounjaro). They were conceived as a treatment for diabetes and were later found to have beneficial effects fighting obesity. They may also help with cardiovascular disease and even neurological disorders such as Alzheimer's. They work by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels and appetite.
Dr Riccardo De Giorgi, Clinical Lecturer in General Adult Psychiatry at the University of Oxford is currently studying the effects of these drugs and admits that it is too soon to know if there is a possible link with depression, but suggests evidence points to a positive, rather negative, impact on mental health.
'The most recent studies available suggest that GLP-1 medications do not increase depressive symptoms or suicidality,' he says. 'These are based on drug trials where the patients were measured for depression 'scores' and psychological wellbeing, and they didn't show a negative effect overall.
'What happens if you are exposed to these drugs and you have a history of depressive episodes? In that regard, we don't have any evidence at all. There are now some more trials pending on depression, but it's very early days.'
I asked around amongst friends and friends of friends (there are so many people using these treatments now that they aren't hard to find), and several reported very similar experiences to my own. One mentioned feeling 'oversensitive and on the verge of tears all the time'. Another said she felt so depressed and exhausted through emotional stress that she had to stop using it. She wanted to start using jabs again but was afraid of reliving her depression. A third said the worst days were 'shocking' but eventually she began to feel better – whether that was because the effects wore off or because she became more adept at coping she couldn't be sure.
For me, the strangest feature of this self-inflicted ordeal was that I couldn't trust my emotions. It was like I was in my own matrix, where what I was experiencing felt real but was actually a simulation I had brought on myself – all while paying a monthly fee for the privilege.
When something bothered me at work, there was no way to measure its real importance, which meant there was no reliable way to respond to it. How could I tell if a crisis at home was trivial, a total catastrophe or something in between? Thinking about the terrible state of Britain and the world suddenly felt deeply personal rather than an essential part of my job. Just hearing the first bars of a John Barry film score or recalling a random memory of my daughters set me off like Adele at an awards ceremony.
I wondered if my new mood was connected to missing food, since I had become a one-meal a day person with no snacking. Maybe giving up eating for pleasure was getting me down? But while I love food like Keir Starmer loves free glasses, not even giving up crisps could make me feel this hopeless.
The accepted routes for treating 'real' depression do not really apply to me since all I needed to do was stop the injections. I could hardly start taking anti-depressants to cope with the artificially induced depression brought on by other drugs.
Therapy to treat it also seemed ridiculous, since it would be treating something that I had the power to stop. That was not a luxury afforded to those unlucky enough to experience the real thing. The therapists I asked about this were none the wiser, expressing confusion about how they might treat a patient who believed their depression had been triggered not by a pre-existing condition or circumstance, but by weight-loss injections. For me, feeling this way was my choice: a trade off for a thinner waist and a current drop of 1st 9lbs.
Dr De Giorgi offered one explanation, yet admits that until he and others are able to conclude further research there is still no clinical evidence of a link between the drugs and depression.
'Some forms of depression are associated with high levels of inflammatory molecules, in which case the anti-inflammatory effects of GLP-1 medications would be helpful,' he explains. 'For other people, who are less prone to inflammation, the drugs might upset the balance in the body that is already in a sweet spot, so the drugs mean you have 'too little inflammation'. A degree of healthy inflammation is needed for the normal upkeep of brain cells. GLP-1 medications seem to be able to enter the brain, so we shouldn't be surprised if we find there are other implications such as mental effects.'
Even if a link was ever proven, which is not likely as things stand, it's hardly going to provide much comfort. Most recently, the icing on this doom-laden cake – the kind a goth would get for his birthday at a Dracula festival in Whitby – was that I began to have nightmares. A mixture of Franz Kafka's brand of horror and Stephen King's It, they were like video nasties in which the lead character shouts: 'This isn't real!' and tries to wake themselves up. After a couple of these, I had to set a deadline to get myself off this stuff. No chiselled jawline is worth this. Kate Moss once famously said: 'Nothing tastes as good as skinny feels', but, for me, it was a case of nothing feels as bad as skinny tastes.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics
We recently published . OPKO Health, Inc. (NASDAQ:OPK) is one of the best healthcare stocks. OPKO Health, Inc. (NASDAQ:OPK) is a diversified healthcare company with operations in diagnostics, pharmaceuticals, and innovative therapies, anchored by BioReference Laboratories and an expanding drug development pipeline. The company is advancing programs in immunology, endocrinology, oncology, and metabolic disorders through both internal research and strategic collaborations. In 2025, OPKO Health, Inc. (NASDAQ:OPK) made notable progress across multiple fronts. In partnership with Merck, it is advancing a Phase 1 trial for an experimental Epstein-Barr virus (EBV) vaccine, which could move to Phase 2 pending trial results. Its metabolic disease pipeline includes OPK-88006, an investigational oral GLP-1/glucagon dual agonist for obesity and metabolic-associated steatohepatitis (MASH). Data presented at ENDO 2025 demonstrated strong bioavailability and efficacy, with both oral and weekly injectable formats in development. The company is also working with Entera Bio on an oral GLP-2 agonist for short bowel syndrome, with promising PK/PD data set for presentation at the 2025 ESPEN Congress. In oncology, the business's subsidiary ModeX is developing multispecific antibody therapeutics, with four clinical candidates, including lymphoma and leukemia treatments, targeting a range of solid tumors and blood cancers, and human trials expected to begin in early 2026. Photo by National Cancer Institute on Unsplash On the diagnostics front, the FDA approved a key update to OPKO's 4KScore Test, allowing use without digital rectal examination data, broadening its role in primary care for prostate cancer risk assessment. Additionally, the planned sale of certain BioReference oncology and clinical testing assets to Labcorp, expected to close in late 2025, will allow OPKO Health, Inc. (NASDAQ:OPK) to sharpen its focus on core diagnostics and pharmaceuticals while improving operational efficiency. While we acknowledge the potential of OPK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
10 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool
Yahoo
11 hours ago
- Yahoo
It's been a long road, but Blood Oxygen tracking is back for the newest Apple Watches in the US – but the feature isn't the same
When you buy through links on our articles, Future and its syndication partners may earn a commission. Following an 18-month ban, Blood Oxygen tracking is coming back to the Apple Watch Series 9, Series 10, and Ultra 2 It's not an entirely on-device experience anymore, though The Apple Watch still measures Blood Oxygen, but the iPhone will calculate and display the final result It's been a long 18 months, but Apple's announced that Blood Oxygen tracking and monitoring are returning to the Apple Watch Series 9, Series 10, and Ultra 2 in the United States. The feature was disabled and effectively banned on the Series 9 and Ultra 2 – then the Series 10, which launched later – after a ruling in January 2024 due to a patent dispute over the technology being used between Massimo and Apple. Now, thanks to iOS 18.6.1 and watchOS 11.6.1, which will roll out later today, the feature is returning in a 'redesigned' form. In its new iteration, the Apple Watch Series 9, Series 10, and Ultra 2's sensors can take a reading, then transmit the data to the connected iPhone, where it will be calculated and displayed in the Health app under 'Respiratory' readings. So no, you won't be able to take the reading, watch as it progresses, and then view the results right on your wrist, as you could before. Still, this does effectively return the tracking and monitoring functionality to the impacted Apple Watch models in the United States. In a statement shared, Apple explains the changes as: 'Users with these models in the U.S. who currently do not have the Blood Oxygen feature will have access to the redesigned Blood Oxygen feature by updating their paired iPhone to iOS 18.6.1, and their Apple Watch to watchOS 11.6.1. Following this update, sensor data from the Blood Oxygen app on Apple Watch will be measured and calculated on the paired iPhone, and results can be viewed in the Respiratory section of the Health app. This update was enabled by a recent U.S. Customs ruling.' The U.S. Customs ruling is key here, as this will return the feature to the Apple Watches sold when the ban began and was subsequently enforced. If you still have an older Apple Watch, or one sold prior to January 2024, the Blood Oxygen functionality remains unimpacted and won't be changed. That also goes for any models sold outside of the United States, which have been unimpacted by this ruling. Still, this does return the Blood Oxygen feature to the Apple Watch, even if it splits the experience between watch and phone. But this separation is likely key to having this allowed and approved by U.S. Customs. For those who have purchased an Apple Watch Series 9, 10, or Ultra 2 in those many months, this is a return to form and rounding out of the health tracking features on Apple's star wearable in the United States. Even in our Apple Watch Series 10 review, we noted that the Blood Oxygen tracking feature was missing in the US. Apple has a pretty smart rollout here, and considering rumors of further pushes into health features that we might see with future generations of Apple Watch models, it might be helpful to have these readings going straight into the Health app. Either route, though, if you've been waiting for Blood Oxygen tracking to return, it's back, but you'll want to make sure your iPhone is nearby if you want to see the results. While Apple has not shared an exact timing for the rollouts of iOS 18.6.1 and watchOS 11.6.1, it has promised to arrive today – August 14, 2025 – in the United States, and we'll update this piece when we see it rolling out. You might also like Constantly dismissing notifications on your Apple Watch? You're going to love Apple's watchOS 26 latest gesture I'm a fitness tracker expert, and here are my top 3 subscription-free picks for 2025 Garmin Venu X1 review: The most innovative Garmin watch in years, and a genuine Apple Watch Ultra rival